中文版 | English
题名

MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China MDR-Chin 研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景

作者
通讯作者Deng,Guofang
发表日期
2024-01-10
DOI
发表期刊
ISSN
1000-6621
卷号46期号:1页码:18-22
摘要
The global trend in the treatment of multidrug-resistant tuberculosis (MDR-TB) is to shorter treatment durations. The MDR-Chin study is China’s first cohort study to explore all-oral short-course regimens for the treatment of MDR-TB and pre-extensive drug-resistant tuberculosis (pre-XDR-TB), validating the efficacy and safety of three different treatment regimens. The results indicated that within a 12-month follow-up after the drug withdrawal, 96% of MDR-TB patients and 83.3% of pre-XDR-TB patients achieved favorable outcomes; the overall rate of favorable outcomes was 92.9%. Although grade 3 or higher adverse events (AEs) were quite common (48.1%), most were manageable and controllable, with relatively rare serious AEs (7.7%). In the study, loss-to-follow-up rate was low, the advantages of the all-oral short-course regimen were reflected and the potential for application in resource-limited settings was displayed. In this article, the author provides an overview of the MDR-Chin study, analyzesthe advantages and disadvantages, and discusses the application and future directions of clinical research for all-oral, short-course treatment regimens in China.
关键词
相关链接[Scopus记录]
语种
中文
学校署名
第一 ; 通讯
Scopus记录号
2-s2.0-85184764699
来源库
Scopus
引用统计
成果类型期刊论文
条目标识符http://sustech.caswiz.com/handle/2SGJ60CL/701589
专题南方科技大学第二附属医院
作者单位
Division Two of Pulmonary Diseases Department,Department of Pulmonary Medicine,Shenzhen Third People’s Hospital,National Clinical Research Center for Infectious Disease (Shenzhen),Shenzhen Clinical Research Center for Tuberculosis,Southern University of Science and Technology,Shenzhen,518000,China
第一作者单位南方科技大学第二附属医院
通讯作者单位南方科技大学第二附属医院
第一作者的第一单位南方科技大学第二附属医院
推荐引用方式
GB/T 7714
Fu,Liang,Deng,Guofang. MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China MDR-Chin 研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景[J]. Chinese Journal of Antituberculosis,2024,46(1):18-22.
APA
Fu,Liang,&Deng,Guofang.(2024).MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China MDR-Chin 研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景.Chinese Journal of Antituberculosis,46(1),18-22.
MLA
Fu,Liang,et al."MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China MDR-Chin 研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景".Chinese Journal of Antituberculosis 46.1(2024):18-22.
条目包含的文件
条目无相关文件。
个性服务
原文链接
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
导出为Excel格式
导出为Csv格式
Altmetrics Score
谷歌学术
谷歌学术中相似的文章
[Fu,Liang]的文章
[Deng,Guofang]的文章
百度学术
百度学术中相似的文章
[Fu,Liang]的文章
[Deng,Guofang]的文章
必应学术
必应学术中相似的文章
[Fu,Liang]的文章
[Deng,Guofang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
[发表评论/异议/意见]
暂无评论

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。